What Is The Optimal Concentration Range Of Bacteriocin-like Substance (BLS) Excreted By Lactobacillus Salivarius To Inhibit The Growth Of Extended-spectrum Beta-lactamase (ESBL)-producing Enterobacteriaceae, While Minimizing The Disruption Of The Indigenous Gut Microbiota In A Murine Model Of Polymicrobial Sepsis?
The optimal concentration range of bacteriocin-like substance (BLS) from Lactobacillus salivarius to inhibit ESBL-producing Enterobacteriaceae while minimizing disruption to the gut microbiota in a murine model of polymicrobial sepsis is determined by balancing efficacy and safety.
-
Efficacy Considerations: BLS must be concentrated enough to effectively target ESBL-producing bacteria, which are resistant to many antibiotics. The concentration should be within the range that inhibits these pathogens, potentially determined by in vitro MIC studies and validated in vivo.
-
Safety Considerations: The concentration should avoid harming indigenous gut microbiota. This requires identifying a threshold below which beneficial bacteria are spared, preventing dysbiosis and maintaining gut health.
-
Mode and Duration of Administration: The method of delivery (e.g., oral) and treatment duration influence BLS distribution and exposure, affecting both efficacy and microbiota impact.
-
Research Findings: Previous studies may have established this range, showing a window where BLS is effective against pathogens without significant microbiota disruption. If not, further research is needed to determine this range.
In conclusion, the optimal BLS concentration is a balanced range that effectively inhibits ESBL-producing bacteria while preserving gut microbiota health, likely identified through experimental studies assessing both antimicrobial efficacy and microbiota composition changes.